Flubromazolam

Placed into Schedule I of the Controlled Substances Act as of January 23, 2023,³⁴ indicating classification as having high abuse potential with no currently accepted medical use.

The CDSA supplies a blanket benzodiazepine-derivative category rather than naming flubromazolam individually.

The current official BtMG Anlage II expressly names Flubromazolam and gives the matching chemical identity under the trafficable-but-non-prescribable Betäubungsmittel heading. BtMG § 1(1) makes Annex II substances Betäubungsmittel, and NpSG § 1(2)(1) excludes those substances from the NpSG. BtMG § 29(1) criminalizes unauthorized dealings and possession without a written acquisition permit, punishable by up to five years' imprisonment or a fine. Authorized BtMG traffic and statutory exceptions mean that the prohibition is not absolute.

The official List II print view names flubromazolam.

The official 7 July 2026 amendment (Dz.U. 2026 poz. 934) adds other substances and leaves flubromazolam's consolidated IV-P listing unchanged.

Flubromazolam is listed in Verzeichnis b, not Verzeichnis E.

The official UNODC Turkey legal-system record identifies flubromazolam as one of the benzodiazepines added to Turkey’s controlled-drug list in 2016 and links the official Gazette text (12 January 2017, No. 29946, Decision No. 2016/9712). The decision is based on Article 19. Turkey’s 2025 official Narkotik report defines NPS as including benzodiazepines, describes the TUBİM Early Warning System (EWS) process for bringing an encountered or risked NPS under Law No. 2313, states that generic classification began in 2015, and reports 1,078 NPS brought under the law through 31 July 2025. The same report identifies Law No. 2313 and TCK Articles 188, 190 and 191 as the principal framework. Under the current Ministry of Justice TCK publication, unlicensed manufacture, import or export is covered by Article 188(1) with 20–30 years’ imprisonment and 2,000–20,000 days’ judicial fine; unlicensed domestic sale, offer, giving, dispatch, transport, storage, purchase, acceptance or possession is covered by Article 188(3) with at least 10 years’ imprisonment and 1,000–20,000 days’ judicial fine. Article 188(6) applies the foregoing rules to substances requiring official authorization or prescription that produce narcotic or stimulant effects. Personal-use purchase, acceptance, possession for use or use is separately covered by Article 191(1) with 2–5 years’ imprisonment, subject to the Article 191(2)–(3) five-year public-prosecution postponement, supervision, possible treatment and testing regime. Article 188(4)(a) has a half-increase for listed categories such as synthetic cannabinoids, synthetic cathinones, synthetic opioids and amphetamine derivatives; flubromazolam is not classified into one of those categories, and no enhancement is identified. Decision No. 2016/9712 lists flubromazolam, but whether that listing remains unchanged in a current consolidated official Law No. 2313 schedule or post-2017 Gazette amendment is uncertain.

Russia's current official Roszdravnadzor consolidation (posted 30 March 2026 and marked amended 11 June 2025) expressly names Фторбромазолам in List III, and Resolution No. 827's official publication record and operative text establish the 2017 addition. List III is a restricted-circulation psychotropic category that allows exclusion of some control measures, rather than a blanket List I prohibition. The compound is individually named, not covered solely as an analogue. Articles 228 and 228.1 provide conduct-, quantity- and intent-dependent criminal penalties; Article 6.8 provides the separate administrative provision. The size table lists 1/5/1000; these values do not establish boundary arithmetic. Product-specific authorization, prescription/dispensing status, and case-specific charging are fact-dependent.

Designated as a Class C controlled substance under the Misuse of Drugs Act 1971 as of May 31, 2017.³³ Possession, production, and supply carry criminal penalties.